Drugs / ADX-626
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07081503 | Aug 2025 → Jan 2027 expected | — | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-03 | ADARx Pharmaceuticals, Inc. | Phase 1 Study of ADX-626 in Healthy Participants adarx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADX-626 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07081503 ↗ |